Oxytocin bei der Geburt – wann und wie viel?

Das Medikament Oxytocin wird in der Geburtshilfe bei protrahiertem Geburtsverlauf präventiv eingesetzt, um maternaler und fetaler Morbidität vorzubeugen. Vor jedem Einsatz müssen individuell die positiven Effekte und die vielfältigen potenziellen Nebenwirkungen abgewogen werden. Die Autorin plädiert für interprofessionell entwickelte klinikinterne Standards, auf die das geburtshilfliche Team regelmäßig geschult wird. Ziel ist es, Betreuungskonzepte für Frauen in der Latenzphase zu entwickeln, um den unnötigen Einsatz von Oxytocin zu vermeiden.

• Literatur

• 1 Abalos E, Oladapo OT, Chamillard M. et al. Duration of spontaneous labour in ‘low-risk’ women with ‘normal’ perinatal outcomes: A systematic review. Eur J Obstet Gynecol Reprod Biol 2018; 223: 123-132 . DOI: 10.1016 / j.ejogrb.2018.02.026.
• 2 Alfirevic Z, Edwards G, Platt MJ. The impact of delivery suite guidelines on intrapartum care in ‘standard primigravida’. Eur J Obstet Gynecol Reprod Biol 2004; 115 (01) : 28-31 . DOI: 10.1016 / j.ejogrb.2003.10.036.
• 3 AQUA- Institut. Bundesauswertung Geburtshilfe. Erfassungsjahr 2014 . Online verfügbar unter https://sqg.de/downloads/Bundesauswertungen/2014/bu_Gesamt_16N1-GEBH_2014.pdf : Stand: 2015
• 4 Berglund S, Grunewald C, Pettersson H. et al. Severe asphyxia due to delivery-related malpractice in Sweden 1990-2005. BJOG 2008; 115 (03) : 316-323 . DOI: 10.1111 / j.1471-0528.2007.01602.x.
• 5 Bernitz S. Øian P, Rolland R. et al. Oxytocin and dystocia as risk factors for adverse birth outcomes: a cohort of low-risk nulliparous women. Midwifery 2014; 30 (03) : 364-370 . DOI: 10.1016 / j.midw.2013.03.010.
• 6 Blix-Lindström S, Johansson E, Christensson K. Midwives’ navigation and perceived power during decision-making related to augmentation of labour. Midwifery 2008; 24 (02) : 190-198 .
• 7 Bosch OJ, Neumann ID. Both oxytocin and vasopressin are mediators of maternal care and aggression in rodents: From central release to sites of action. Review. Hormones and Behavior 2012; 61 (03) : 293-303 .
• 8 Brimdyr K, Cadwell K, Widström AM. et al. The effect of labor medications on normal newborn behavior in the first hour after birth: A prospective cohort study. Early hum dev 2019; 132: 30-36 . DOI: 10.1016 / j.earlhumdev.2019.03.019.
• 9 Budden A, Chen LJ, Henry A. High-dose versus low-dose oxytocin infusion regimens for induction of labour at term. Cochrane Database Syst Rev. 2014 (10): CD009701 . DOI: 10.1002 / 14651858.CD009701.pub2.
• 10 Bugg GJ, Siddiqui F, Thornton JG. Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour. Cochrane Database Syst Rev 2013 (6): CD007123 . DOI: 10.1002 / 14651858.CD007123.pub3.
• 11 Carroli G, Cuesta C, Abalos E. et al. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol 2008; 22 (06) : 999-1012 .
• 12 Clark SL, Simpson KR, Knox GE. Oxytocin: new perspectives on an old drug. Am J Obstet Gynecol 2009; 200 (35) : 35e1-35e6 .
• 13 Daniel-Spiegel E, Weiner Z, Ben-Shlomo I. et al. For how long should oxytocin be continued during induction of labour? BJOG 2004; 111: 331-334 .
• 14 Erickson EN, Emeis CL. Breastfeeding Outcomes After Oxytocin Use During Childbirth: An Integrative Review. J Midwifery Womens Health 2017; 62 (04) : 397-417 . DOI: 10.1111 / jmwh.12601.
• 15 Friedman EA. The graphic analysis of labor. Am J Obstet Gynecol 1954; 68 (06) : 1568-1575 . DOI: 10.1016 / 0002-9378(54)90311-7.
• 16 Gaudernack LC, Frøslie KF, Michelsen TM. et al. De-medicalization of birth by reducing the use of oxytocin for augmentation among first-time mothers - a prospective intervention study. BMC pregnancy and childbirth 2018; 18 (01) : 76 . DOI: 10.1186 / s12884-018-1706-4.
• 17 Grotegut CA, Paglia MJ, Johnson LN. et al. Oxytocin exposure during labor among women with postpartum hemorrhage secondary to uterine atony. Am J Obstet Gynecol 2011; 204 (01) : 56. e1-6 . DOI: 10.1016 / j.ajog.2010.08.023.
• 18 Hernández-Martínez A, Arias-Arias Angel, Morandeira-Rivas Antonio. et al. Oxytocin discontinuation after the active phase of induced labor: A systematic review. Women birth 2019; 32 (02) : 112-118 . DOI: 10.1016 / j.wombi.2018.07.003.
• 19 Hodnett ED, Stremler R, Willan AR. et al. Effect on birth outcomes of a formalised approach to care in hospital labour assessment units: international, randomised controlled trial. BMJ 2008; 337: a1021 . DOI: 10.1136 / bmj.a1021.
• 20 Jackson JK, Wickstrom E, Anderson B. Oxytocin Guidelines Associated with Compliance to National Standards. MCN Am J Matern Child Nurs 2019; 44 (03) : 128-136 .
• 21 Jackson JK, Wickstrom E, Anderson B. Oxytocin-Guidelines. Associated with Compliance to National Standards. MCN Am J Matern Child Nurs 2019; 44 (03) : 128-136 .
• 22 Kenkel WM, Perkeybile AM, Yee JR. et al. Behavioral and epigenetic consequences of oxytocin treatment at birth. Science Advanced 2019; 5: 1-10 .
• 23 Kjaergaard H, Olsen J, Ottesen B. et al. Incidence and outcomes of dystocia in the active phase of labor in term nulliparous women with spontaneous labor onset. Acta Obstet Gynecol Scand 2009; 88 (04) : 402-407 . DOI: 10.1080 / 00016340902811001.
• 24 Liu J, Yi Y, Weiwei X. Effects of Increased Frequency, High Dose, and Pulsatile Oxytocin Regimens on Abnormal Labor Delivery. Med Sci Monit 2018; 24: 2063-2071 . DOI: 10.12659 / msm.906728.
• 25 National Institute for Health and Care Excellence. Intrapartum care for healthy women and Intrapartum care for healthy women and babies babies. Clinical Guideline. https://www.nice.org.uk/guidance/cg190 : Stand: 2014
• 26 Odent MR. Synthetic oxytocin and breastfeeding: reasons for testing an hypothesis. Medical hypotheses 2013; 81 (05) : 889-891 . DOI: 10.1016 / j.mehy.2013.07.044.
• 27 Page K, McCool WF, Guidera M. Examination of the Pharmacology of Oxytocin and Clinical Guidelines for Use in Labor. J Midwifery Womens Health 2017; 62 (04) : 425-433 . DOI: 10.1111 / jmwh.12610.
• 28 Rath W. Medikamentöse Geburtseinleitung mit Oxytocin und Prostaglandinen - ein kurzer historischer Abriß. Hg. v. W. Rath. 1996
• 29 Rath W, Gogarten W. Oxytocin und Methylergometrin nach der Geburt – Vorsicht bei der Anwendung! Frauenarzt 2008; 49 (06) : 498-503 .
• 30 Rody A, Liedtke C. (Hg.). Molekulare Gynäkologie und Geburtshilfe für die Praxis. Ursachen verstehen- gezielt therapieren. 1.. Aufl. Stuttgart: Thieme; 2016
• 31 Romijn A, Muijtjens IA, Bruijne C. et al. What is normal progress in the first stage of labour? A vignette study of similarities and differences between midwives and obstetricians. Midwifery 2016; 41: 104-109 . DOI: 10.1016 / j.midw.2016.08.006.
• 32 Rygh AB, Skjeldestad FE, Körner Hartwig. et al. Assessing the association of oxytocin augmentation with obstetric anal sphincter injury in nulliparous women: a population-based, case-control study. BMJ open 2014; : 4 (07) : e004592 . DOI: 10.1136 / bmjopen-2013-004592.
• 33 Selin L, Almström E, Wallin G. et al. Use and abuse of oxytocin for augmentation of labor. Acta Obstet Gynecol Scand 2009; 88 (12) : 1352-1357 . DOI: 10.3109 / 00016340903358812.
• 34 Vogel JP, Williams M, Gallos I. et al. WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? BMJ Glob Health 2019; 4 (02) : e001466 . DOI: 10.1136 / bmjgh-2019-001466.
• 35 WHO. WHO recommendations: intrapartum care for a positive childbirth experience. Geneva: World Health Organisation; 2018: 1-201 .
• 36 Winkler M, Rath W. Medikamentöse Geburtseinleitung. Indikationen und Methoden. Der Gynäkologe 1998; 31: 562-575 .
• 37 Zhang L, Troendle J, Branch DWare. et al. The expected labor progression after labor augmentation with oxytocin: A retrospective cohort study. PloS one 2018; 13 (10) : e0205735 . DOI: 10.1371 / journal.pone.0205735